Podcast Beta
Questions and Answers
Which condition is NOT commonly treated with Calcium Channel Blockers (CCB), specifically non-dihydropyridines?
What is the primary mechanism of action of non-dihydropyridine CCBs?
Which of the following is a serious side effect associated with non-dihydropyridine CCBs?
When should the heart rate and blood pressure be assessed concerning the administration of calcium channel blockers?
Signup and view all the answers
Why are non-dihydropyridine calcium channel blockers not considered a first-line agent for hypertension?
Signup and view all the answers
Study Notes
Calcium Channel Blockers (CCB) - Non-dihydropyridines
- Verapamil and Diltiazem are examples of non-dihydropyridine CCBs.
- Non-dihydropyridine CCBs relax vascular smooth muscle, leading to vasodilation.
- Additionally, these drugs decrease cardiac cellular excitability and contractility.
- Therapeutic uses of non-dihydropyridine CCBs include treatment of angina, atrial fibrillation, hypertension, and supraventricular tachycardia (SVT).
- Potential adverse effects include dysrhythmias.
- Assess heart rate and blood pressure prior to administering non-dihydropyridine CCBs.
- Non-dihydropyridine CCBs are not typically considered first-line agents for hypertension.
Studying That Suits You
Use AI to generate personalized quizzes and flashcards to suit your learning preferences.
Description
This quiz covers the non-dihydropyridine calcium channel blockers, specifically Verapamil and Diltiazem. You'll learn about their mechanisms of action, therapeutic uses, and potential adverse effects, as well as considerations for patient assessment before administration. Test your knowledge on their role in treating conditions such as hypertension and atrial fibrillation.
